# Formula N-5550: Advanced Multi-Target Cognitive & Metabolic Enhancement

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Overview

**Formula Classification:** Multi-pathway neuro-metabolic modulator – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**
- Dihexa – 5 mg
- Tesofensine – 0.5 mg
- Methylene Blue – 50 mg

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to protect the components and ensure optimal absorption.

**Therapeutic Intent:**
- To provide a powerful, synergistic approach to cognitive enhancement and weight management by simultaneously targeting structural neuroplasticity, neurochemical balance, and mitochondrial function. This formula is designed for individuals seeking significant improvements in memory, focus, and mood, coupled with effective appetite suppression and metabolic support.

---

## 2. Detailed Mechanism of Action

Formula N-5550 integrates three distinct but highly synergistic agents to optimize both brain and body function.

### 2.1 Dihexa: Structural Neuroplasticity

Dihexa is a potent peptide that activates the HGF/c-Met pathway, a critical system for neuronal growth and repair. It promotes robust synaptogenesis, physically increasing the brain's capacity for learning and memory [1].

### 2.2 Tesofensine: Neurochemical & Metabolic Modulation

Tesofensine is a triple reuptake inhibitor of serotonin, norepinephrine, and dopamine. This action increases the availability of these key neurotransmitters, enhancing focus, mood, and motivation. It also has a powerful appetite-suppressant effect, leading to significant weight loss [2].

### 2.3 Methylene Blue: Mitochondrial & Neurochemical Enhancement

At low doses, Methylene Blue acts as a mitochondrial redox cycler, enhancing ATP production and reducing oxidative stress [3]. It is also a reversible inhibitor of MAO-A, which synergistically increases serotonin and norepinephrine levels, complementing the action of Tesofensine [4].

---

## 3. Synergistic Integration Table

| Level | Primary Pathway | Key Components | Integrated Clinical Effect |
|---|---|---|---|
| Structural | Synaptogenesis | Dihexa | Long-term enhancement of neural architecture and memory capacity. |
| Neurochemical | Monoamine Modulation | Tesofensine, Methylene Blue | Potent, synergistic increase in serotonin, norepinephrine, and dopamine for enhanced mood, focus, and appetite control. |
| Metabolic | Energy & Appetite | Tesofensine, Methylene Blue | Increased resting energy expenditure, significant appetite suppression, and optimized cellular energy production. |

---

## 4. Key Clinical Benefits

| Domain | Key Benefits |
|---|---|
| Cognitive Function | Improved memory, focus, and processing speed; enhanced executive function. |
| Weight Management | Significant, clinically proven weight loss through appetite suppression and metabolic enhancement. |
| Mood & Energy | Elevated mood, increased motivation, and sustained mental and physical energy. |
| Neuroprotection | Promotion of neural plasticity and resilience against oxidative stress. |

---

## 5. Patient Expectations & Timeline

| Timeframe | Expected Changes |
|---|---|
| 1-3 Days | Initial increase in energy, focus, and mood. Noticeable reduction in appetite. |
| 1-2 Weeks | Consistent cognitive and mood enhancement. Significant reduction in food cravings and caloric intake. Initial weight loss becomes apparent. |
| 1-3 Months | Substantial weight loss. Significant improvements in memory, learning, and overall cognitive function. |
| 3-6+ Months | Sustained cognitive benefits and achievement of weight management goals. Long-term neuroprotective effects. |

---

## 6. Dosing & Administration

- **Standard Dose:** One capsule daily in the morning.
- **Timing:** Morning administration is crucial to avoid sleep disruption.
- **Optimization:** Start with a lower dose or every-other-day dosing to assess tolerance, particularly to the stimulating effects of Tesofensine.

---

## 7. Safety Profile

- **Overall:** A powerful formula that requires careful patient selection and monitoring.
- **Absolute Contraindications:** Use of SSRIs, SNRIs, other MAOIs, or any other serotonergic drugs (high risk of serotonin syndrome). A 2-4 week washout period is mandatory. Severe or uncontrolled cardiovascular disease. History of psychiatric disorders such as bipolar disorder or psychosis. Pregnancy and lactation.
- **Relative Cautions:** Controlled hypertension (monitor BP closely). History of anxiety or panic attacks.
- **Tolerability:** Common side effects include dry mouth, insomnia (if taken too late), increased heart rate, and elevated blood pressure. The blue/green discoloration of urine from Methylene Blue is harmless.

---

## 8. Drug Interaction Considerations

| Drug/Class | Interaction / Management |
|---|---|
| **Serotonergic Agents (SSRIs, SNRIs, TCAs, MAOIs, Triptans, Tramadol)** | **ABSOLUTELY CONTRAINDICATED.** High risk of life-threatening serotonin syndrome. |
| Stimulants (e.g., Amphetamine, Methylphenidate) | Additive effects on heart rate and blood pressure; use with extreme caution. |
| Antihypertensives | May counteract the effects of antihypertensive medications; monitor BP closely. |
| Dopaminergic Agents (e.g., L-DOPA) | Potential for additive effects; use with caution. |

---

## 9. References

[1] Sun, X., et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. *Brain Sciences*, 11(11), 1487.

[2] Astrup, A., et al. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. *The Lancet*, 372(9653), 1906-1913.

[3] Rojas, J. C., & Gonzalez-Lima, F. (2013). Low-dose methylene blue: a novel and promising neuroprotective agent for neurodegenerative disorders. *Molecular Neurobiology*, 48(3), 525-535.

[4] Ramsay, R. R., et al. (2007). A site-directed inhibitor of monoamine oxidase: Methylene blue. *Journal of Neural Transmission*, 114(6), 783-786.
